Cullinan Management (NASDAQ:CGEM) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Cullinan Management and BioAtla, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Cullinan Management | 0 | 1 | 3 | 0 | 2.75 |
BioAtla | 0 | 0 | 4 | 0 | 3.00 |
Cullinan Management currently has a consensus price target of $48.00, suggesting a potential upside of 18.75%. BioAtla has a consensus price target of $48.00, suggesting a potential downside of 9.60%. Given Cullinan Management's higher probable upside, equities analysts clearly believe Cullinan Management is more favorable than BioAtla.
Earnings & Valuation
This table compares Cullinan Management and BioAtla's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Cullinan Management | N/A | N/A | N/A | N/A | N/A |
BioAtla | N/A | N/A | N/A | N/A | N/A |
Profitability
This table compares Cullinan Management and BioAtla's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Cullinan Management | N/A | N/A | N/A |
BioAtla | N/A | N/A | N/A |
Summary
BioAtla beats Cullinan Management on 2 of the 3 factors compared between the two stocks.